초록 close

Much effort has been made to find reliable indicators predicting the treatment response in subjects with panic disorder. The objective of this study was to determine the effect of pharmacotherapy on the biofeedback measurement variables in patients with panic disorder. We recruited 38 patients with panic disorder (M; 25, F; 13) being treated in the Samsung Medical Center, who were diagnosed by the ADIS-IV (Anxiety Disorder Interview Schedule-IV), and 33 normal control subjects (M; 21 F; 12). The panic patients were treated with paroxetine for 3 months. All of the subjects were assessed by means of forearm and frontal electromyography (EMG), electrodermal response (EDR), and peripheral skin temperature in the baseline, stress, and recovery phases using the Procomp & Biograph biofeedback instrument. Psychological measures, viz. the Hamilton anxiety rating scale(HAM-A), Hamilton depression rating scale (HAM-D), Beck depression inventory (BDI), Spielberger state-trait anxiety inventory(STAI-S, STAI-T), and Anxiety sensitivity index (ASI), were also assessed. All measurements were performed at the beginning of the study and after 3 months of paroxetine treatment. The panic patients had significantly higher scores on the psychological measures, viz. the HAM-A, HAM-D, BDI, STAI-S, STAI-T, and ASI (all p values<0.001) before treatment. After 3 months of treatment, the panic patients showed a significant improvement as compared to the baseline EDR (z=-2.824, p=0.005), stress EDR (z=-2.691, p=0.007) and recovery EDR (z=-3.416, p=0.001). They also showed a significant improvement in terms of the HAM-A, HAM-D, BDI, STAI-S, STAI-T, and ASI (all p values <0.001) after treatment. The electrodermal response, which is one of the biofeedback measurement variables, was found to be a possible indicator predicting treatment response in panic disorder.